DUBLIN--(BUSINESS WIRE)--Aug 20, 2018--The "Protein Design & Engineering" conference has been added to ResearchAndMarkets.com's offering.

Protein-based drugs are a fast-growing class on the pharmaceutical market, with thousands of candidates in development.

State-of-the-art technologies in computational protein design and experimental protein engineering are needed to accelerate the process of biotherapeutic design. Industrial meetings on drug design frequently miss the new computational and experimental methodologies introduced by a few academic labs around the world.

On the other hand, university environment rarely allows for high-throughput testing of the new technologies. To bridge this gap between industry and academia, we initiated the meeting on Protein Design and Engineering and assembled a panel of world-class scientists.

We invite you to join us to experience the live case studies and discussions from the experts of industry and institutes across the globe. The meeting should stimulate exchange of ideas and collaborative research between industry and academia.

Agenda

Structural methods in drug design Protein design and analysis Structure based drug development Proteome microarray based approach Design binding specificity Human-like recombinant antibodies Glycoengineered antibodies

For more information about this conference visit https://www.researchandmarkets.com/research/xztm44/2_day_conference?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180820005296/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Engineering,Proteomics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/20/2018 08:50 AM/DISC: 08/20/2018 08:50 AM

http://www.businesswire.com/news/home/20180820005296/en